Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00185341 |
The purpose of this study is to investigate if SH T 04268H is effective in the treatment of endometriosis associated pelvic pain.
Condition | Intervention | Phase |
---|---|---|
Endometriosis |
Drug: SH T 04268H |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of a Chemokine Receptor Antagonist Given Orally for the Treatment of Endometriosis |
Study Start Date: | February 2005 |
Study Completion Date: | February 2007 |
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 308601, EudraCT No. 2004-000630-37 |
Study First Received: | September 12, 2005 |
Last Updated: | April 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00185341 |
Health Authority: | Finland: National Agency for Medicines; Sweden: Medical Products Agency; Spain: Ministry of Health and Consumption; Denmark: Laegemiddelsstryrelsen; Czech Republic: State Institute for Drug Control |
Endometriosis associated pelvic pain |
Genital Diseases, Female Pelvic Pain Endometriosis Pain |